ETR: BIO Statistics

Total Valuation

Biotest Aktiengesellschaft has a market cap or net worth of EUR 1.33 billion. The enterprise value is 1.92 billion.

Market Cap	1.33B
Enterprise Value	1.92B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.87%
Shares Change (QoQ)	-7.96%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	20.35M

Valuation Ratios

The trailing PE ratio is 19.41.

PE Ratio	19.41
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	2.60
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.69, with an EV/FCF ratio of 34.08.

EV / Earnings	28.01
EV / Sales	2.71
EV / EBITDA	17.69
EV / EBIT	26.36
EV / FCF	34.08

Financial Position

The company has a current ratio of 2.54, with a Debt / Equity ratio of 1.16.

Current Ratio	2.54
Quick Ratio	0.71
Debt / Equity	1.16
Debt / EBITDA	5.81
Debt / FCF	10.90
Interest Coverage	2.20

Financial Efficiency

Return on equity (ROE) is 13.87% and return on invested capital (ROIC) is 3.81%.

Return on Equity (ROE)	13.87%
Return on Assets (ROA)	3.25%
Return on Capital (ROIC)	3.81%
Revenue Per Employee	291,426
Profits Per Employee	28,236
Employee Count	2,426
Asset Turnover	0.52
Inventory Turnover	1.07

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.76% in the last 52 weeks. The beta is 0.24, so Biotest Aktiengesellschaft's price volatility has been lower than the market average.

Beta (5Y)	0.24
52-Week Price Change	-3.76%
50-Day Moving Average	41.51
200-Day Moving Average	41.69
Relative Strength Index (RSI)	48.12
Average Volume (20 Days)	155

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biotest Aktiengesellschaft had revenue of EUR 707.00 million and earned 68.50 million in profits. Earnings per share was 1.73.

Revenue	707.00M
Gross Profit	247.70M
Operating Income	70.00M
Pretax Income	54.80M
Net Income	68.50M
EBITDA	100.25M
EBIT	70.00M
Earnings Per Share (EPS)	1.73

Full Income Statement

Balance Sheet

The company has 24.70 million in cash and 613.90 million in debt, giving a net cash position of -589.20 million.

Cash & Cash Equivalents	24.70M
Total Debt	613.90M
Net Cash	-589.20M
Net Cash Per Share	n/a
Equity (Book Value)	527.50M
Book Value Per Share	14.18
Working Capital	427.40M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 89.70 million and capital expenditures -33.40 million, giving a free cash flow of 56.30 million.

Operating Cash Flow	89.70M
Capital Expenditures	-33.40M
Free Cash Flow	56.30M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 35.04%, with operating and profit margins of 9.90% and 9.69%.

Gross Margin	35.04%
Operating Margin	9.90%
Pretax Margin	7.75%
Profit Margin	9.69%
EBITDA Margin	14.18%
EBIT Margin	9.90%
FCF Margin	7.96%

Dividends & Yields

Biotest Aktiengesellschaft does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.87%
Shareholder Yield	0.87%
Earnings Yield	4.18%
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on July 15, 2015. It was a forward split with a ratio of 3.

Last Split Date	Jul 15, 2015
Split Type	Forward
Split Ratio	3

Scores

Biotest Aktiengesellschaft has an Altman Z-Score of 2.38. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.38
Piotroski F-Score	n/a